Constipation Laxative Market 2025

Constipation Laxative Market Size

The global constipation laxative market reached a value of nearly $6,996.58 million in 2024, having grown at a compound annual growth rate (CAGR) of 4.81% since 2019. The market is expected to grow from $6,996.58 million in 2024 to $9,268.81 million in 2029 at a rate of 5.79%. The market is then expected to grow at a CAGR of 5.27% from 2029 and reach $11,983.56 million in 2034. Growth in the historic period resulted from strong economy, rapid growth of unmanned aerial system and growing aerospace industry. Factors that negatively affected growth in the historic period were supply chain disruptions. Going forward, rapid urbanization, expansion of defense budgets, growing demand for air travel, expanding tourism sector, increasing aircraft production and favorable government support will drive the growth. Factor that could hinder the growth of the aerospace forging market in the future include lack of skilled labor.

Constipation Laxative Market Drivers

The key drivers of the constipation laxative market include: Growth In Preventive Healthcare The growth in preventive healthcare supported the growth of the constipation laxative market in the historic period. As more consumers focused on maintaining overall wellness and avoiding chronic health issues, there was an increased demand for products that support digestive health and regular bowel function. This shift in consumer behavior led to higher adoption of over-the-counter laxatives as part of routine health management, boosting market growth. For instance, in November 2023, according to a survey conducted among 1,000 people by India Brand Equity Foundation, a Trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India, at least 40% of respondents strongly preferred preventative health. Therefore, the growth in preventive healthcare drove the growth of the constipation laxative market.

Constipation Laxative Market Restraints

The key restraints on the constipation laxative market include: Stringent FDA And EMA Regulations Stringent U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regulations hindered the growth of the constipation laxative market, in historic period. These regulatory bodies enforce strict approval processes and quality standards for both prescription and over-the-counter laxatives, which led to longer development timelines, higher compliance costs and delays in product launches. As a result, market entry for new products was restricted, reducing innovation and slowing overall market expansion. For instance, in June 2023, the FDA approved linaclotide (Linzess) as the first treatment for functional constipation in children aged 6–17, following positive and controlled clinical trials. There is a clear warning against use in children under 2 years due to safety concerns. Therefore, the stringent U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regulations restrained the growth of the constipation laxative market.

Constipation Laxative Market Trends

Major trends shaping the constipation laxative market include: Expanding Access To Affordable Gastrointestinal Therapies Through Generic Drug Development Companies operating in the constipation laxative market are focusing on developing generic drug, to offer cost-effective alternatives to branded medications and increase accessibility for a broader patient population. The aim is to strengthen their presence in the competitive gastrointestinal therapeutics segment. For instance, in June 2025, Lupin Limited, an India-based pharmaceutical company, launched Prucalopride Tablets (1 mg and 2 mg) in the U.S. after securing approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA). These tablets are the generic equivalents of Takeda’s Motegrity and are prescribed for the treatment of chronic idiopathic constipation (CIC) in adults. The launch expands Lupin’s U.S. gastrointestinal portfolio and addresses the growing demand for cost-effective treatments. The reference drug, Motegrity, recorded approximately USD 184 million in annual U.S. sales, highlighting a significant market opportunity. Innovative Therapeutic Advancements Driving Enhanced Constipation Management Major companies operating in the constipation laxative market are focusing on the advancements such as development and launch of first-in-class drugs with novel mechanisms of action, to prove therapeutic effectiveness, offer targeted relief, differentiate their product portfolios and meet the growing demand for safer and more efficient constipation treatments. For instance, in October 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Elobixibat in India under the brand name BixiBat, following approval from the Central Drugs Standard Control Organisation (CDSCO) after successful Phase-3 trials. As the first company to introduce this first-in-class drug in India, Dr. Reddy’s aims to address chronic constipation by offering a novel mechanism that enhances bowel movement through bile acid modulation. Backed by its strong gastrointestinal portfolio, the company views this launch as a step toward advancing treatment standards and meeting unmet patient needs in India.

Opportunities And Recommendations In The Constipation Laxative Market

Opportunities – The top opportunities in the constipation laxative market segmented by route of administration will arise in the oral segment, which will gain $1,517.31 million of global annual sales by 2029. The top opportunities in the constipation laxative market segmented by distribution channel will arise in the online pharmacies segment, which will gain $900.20 million of global annual sales by 2029. The constipation laxative market size will gain the most in the USA at $608.63 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the constipation laxative companies to focus on expanding generic drug portfolios to capture demand for cost-effective treatments, focus on advancing novel constipation treatments through first-in-class drug development, focus on innovation in product development to strengthen market presence, focus on osmotic laxatives for growth, expand in emerging markets, continue to focus on developed markets, focus on strengthening distribution networks for wider market reach, focus on balanced pricing strategies for constipation laxatives, focus on targeted awareness campaigns, focus on differentiated promotional channels, focus on targeting end-user segments through demographic and behavioral insights.